SCHEMBL7084597

SCHEMBL7084597

O=C(Cc1ccccc1Cl)Nc1ccc(C(=O)C[N+](=O)[O-])c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ5 P48544 7/20 0.55
KCNJ3 P48549 7/20 0.55
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
KCNJ6 P48051 3/20 0.50
CLK2 P49760 1/20 0.49
PRKX P51817 1/20 0.49
CAMK2D Q13557 1/20 0.49
PKN2 Q16513 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
STK17A Q9UEE5 1/20 0.49
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
THRB P10828 1/20 0.47
P2RX4 Q99571 5/20 0.46
NR1I2 O75469 1/20 0.45
NPC1 O15118 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7085104 0.90 KMT2A (0.51) KCNJ5KCNJ3MEN1KMT2AKDM4E
SCHEMBL7085428 0.87 KCNJ5 (0.55) KCNJ5KCNJ3MEN1KMT2AKDM4E
SCHEMBL7088706 0.87 MEN1 (0.60) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL7223248 0.84 MEN1 (0.43) KCNJ5KCNJ3MEN1KMT2AKDM4E
SCHEMBL7088364 0.82 MEN1 (0.58) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL7088770 0.82 MEN1 (0.55) KCNJ5KCNJ3MEN1KMT2AKDM4E
SCHEMBL7088341 0.81 MEN1 (0.52) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL7088124 0.81 KMT2A (0.59) KCNJ5KCNJ3MEN1KMT2AKDM4E
SCHEMBL7086210 0.81 KMT2A (0.42) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL7090480 0.81 MEN1 (0.56) MEN1KMT2AALDH1A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 KCNJ5 2079/4885KCNJ3 2267/4885MEN1 3488/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 KCNJ5 2235/4885KCNJ3 2338/4885MEN1 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.